A Phase 2 interventional study of ARO-APOC3 and Placebo in Mixed Dyslipidemia, sponsored by Arrowhead Pharmaceuticals. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.
Among the 349 studies in Dyslipidemias with a site in United States, this one is the 78th largest by enrollment of the 316 interventional ones that give a count, is one of 10 that started in 2021, is one of 66 in phase 2, and was the 283rd registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Connecticut · Sites in United States
Ages 18–64
University of Georgia · Sites in United States
Ages 25–75 · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–70
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 75 · Phase 3 76 · Phase 4 23
First in 1976; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 105 across the 316 interventional studies, 140 across the 31 observational. Of the 299 that completed or were terminated, 125 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
170 of 349 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.
Arrowhead Pharmaceuticals has 5 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyslipidemias with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06496243NewAmsterdam PharmaImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | 2026-11 |
| NCT06382298University of GeorgiaCottonseed Oil Versus Matched PUFA Effects | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 349 studies in Dyslipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.
Key Inclusion Criteria:
Based on medical history, prior evidence of triglycerides (TG) ≥ 150 milligrams (mg)/deciliter (dL) and ≤ 499 mg/dL
Key Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARO-APOC3 10 milligrams (mg) subcutaneous (SC) injection on Day 1 and Week 12 (Q12W) for a total of 2 injections
Drug: ARO-APOC3
ARO-APOC3 25 mg SC injection on Day 1 and Week 12 (Q12W) for a total of 2 injections
Drug: ARO-APOC3
ARO-APOC3 50 mg SC injection on Day 1 and Week 12 (Q12W) for a total of 2 injections
Drug: ARO-APOC3
ARO-APOC3 50 mg SC injection on Day 1 and Week 24 (Q24W) for a total of 2 injections
Drug: ARO-APOC3
Volume-matched placebo SC injection on Day 1 and Week 12 for a total of 2 injections
Drug: Placebo
ARO-APOC3 Injection
Also known as: Plozasiran
Sterile Normal Saline (0.9% NaCl)
Percent Change From Baseline at Week 24 in Fasting TG
Least square (LS) mean and standard error (SE) were calculated using mixed model repeated measures (MMRM) which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting TG
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/early termination (ET)
Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in ApoC-III
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting Non-HDL-C
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C)
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting HDL-C
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB)
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting Total ApoB
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C)
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Week 24
Percent Change From Baseline Over Time Through Week 48 in Fasting LDL-C
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48/ET
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence, which did not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) was an AE that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or was a medically important event or reaction. TEAEs were AEs that occurred following study drug administration or a pre-existing condition exacerbated following study drug administration.
Time frame: Up to Week 48
| Milestone | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Started | 87 | 67 | 67 | 66 | 66 |
| Received at least 1 dose of study drug | 87 | 67 | 67 | 66 | 66 |
| Completed | 78 | 60 | 64 | 61 | 61 |
| Not completed | 9 | 7 | 3 | 5 | 5 |
| Withdrew: Withdrawal by subject | 3 | 3 | 1 | 1 | 2 |
| Withdrew: Physician decision | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 0 | 1 |
Least square (LS) mean and standard error (SE) were calculated using mixed model repeated measures (MMRM) which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting TG | -1.7 ± 3.07 | -51.5 ± 3.54 | -57.7 ± 3.49 | -64.1 ± 3.51 | -45.9 ± 3.52 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Change at Week 4 | -0.5 ± 2.77 | -51.4 ± 3.21 | -61.5 ± 3.14 | -66.4 ± 3.20 | -62.5 ± 3.19 |
| Change at Week 8 | -0.4 ± 2.45 | -48.6 ± 2.78 | -58.1 ± 2.77 | -65.0 ± 2.78 | -59.7 ± 2.78 |
| Change at Week 12 | -0.1 ± 3.07 | -43.8 ± 3.46 | -53.6 ± 3.50 | -57.9 ± 3.45 | -51.7 ± 3.49 |
| Change at Week 16 | -1.8 ± 2.87 | -58.0 ± 3.21 | -62.0 ± 3.21 | -68.3 ± 3.21 | -50.6 ± 3.17 |
| Change at Week 20 | 1.2 ± 2.85 | -54.6 ± 3.32 | -62.0 ± 3.28 | -64.7 ± 3.28 | -49.1 ± 3.23 |
| Change at Week 24 | -1.7 ± 3.07 | -51.5 ± 3.54 | -57.7 ± 3.49 | -64.1 ± 3.51 | -45.9 ± 3.52 |
| Change at Week 28 | 3.5 ± 2.95 | -46.2 ± 3.41 | -55.7 ± 3.35 | -61.7 ± 3.38 | -63.4 ± 3.39 |
| Change at Week 36 | 6.1 ± 4.66 | -44.7 ± 5.35 | -51.5 ± 5.25 | -54.9 ± 5.34 | -60.1 ± 5.32 |
| Change at Week 48/ET | 1.7 ± 4.35 | -33.2 ± 4.96 | -42.8 ± 4.86 | -50.2 ± 4.94 | -55.0 ± 4.93 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Apolipoprotein (Apo)C-III | 23.9 ± 21.90 | -58.9 ± 24.86 | -44.3 ± 24.54 | -65.7 ± 24.71 | -57.9 ± 24.70 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Change at Week 4 | 19.3 ± 21.81 | -60.7 ± 24.78 | -69.7 ± 24.45 | -78.4 ± 24.66 | -82.7 ± 24.64 |
| Change at Week 8 | 19.0 ± 21.84 | -57.3 ± 24.72 | -61.9 ± 24.48 | -71.8 ± 24.64 | -78.1 ± 24.62 |
| Change at Week 12 | 20.3 ± 21.90 | -48.7 ± 24.77 | -18.9 ± 24.57 | -59.2 ± 24.66 | -71.5 ± 24.68 |
| Change at Week 16 | 10.9 ± 21.92 | -69.9 ± 24.79 | -63.8 ± 24.54 | -78.9 ± 24.67 | -67.7 ± 24.62 |
| Change at Week 20 | 21.8 ± 21.88 | -64.0 ± 24.87 | -63.3 ± 24.58 | -69.3 ± 24.72 | -62.6 ± 24.65 |
| Change at Week 24 | 23.9 ± 21.90 | -58.9 ± 24.86 | -44.3 ± 24.54 | -65.7 ± 24.71 | -57.9 ± 24.70 |
| Change at Week 28 | 35.6 ± 21.90 | -51.7 ± 24.87 | -32.8 ± 24.55 | -53.3 ± 24.71 | -82.5 ± 24.70 |
| Change at Week 36 | 30.6 ± 21.96 | -46.3 ± 24.91 | -24.9 ± 24.58 | -34.5 ± 24.74 | -75.8 ± 24.70 |
| Change at Week 48/ET | 27.3 ± 21.97 | -31.2 ± 24.97 | -13.9 ± 24.58 | -17.4 ± 24.78 | -64.8 ± 24.72 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) | -2.7 ± 2.56 | -19.3 ± 2.93 | -20.1 ± 2.90 | -26.9 ± 2.92 | -10.3 ± 2.92 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Change at Week 4 | -1.2 ± 2.19 | -17.3 ± 2.53 | -23.3 ± 2.48 | -26.3 ± 2.52 | -19.6 ± 2.53 |
| Change at Week 8 | -1.0 ± 2.37 | -18.2 ± 2.69 | -22.4 ± 2.67 | -27.8 ± 2.70 | -16.2 ± 2.70 |
| Change at Week 12 | -0.4 ± 2.65 | -15.5 ± 3.00 | -19.4 ± 3.01 | -21.9 ± 3.00 | -16.0 ± 3.02 |
| Change at Week 16 | -1.4 ± 2.49 | -21.2 ± 2.80 | -23.8 ± 2.80 | -28.5 ± 2.81 | -15.5 ± 2.79 |
| Change at Week 20 | -1.9 ± 2.82 | -20.9 ± 3.24 | -21.5 ± 3.21 | -27.3 ± 3.22 | -11.7 ± 3.20 |
| Change at Week 24 | -2.7 ± 2.56 | -19.3 ± 2.93 | -20.1 ± 2.90 | -26.9 ± 2.92 | -10.3 ± 2.92 |
| Change at Week 28 | 0.4 ± 2.91 | -17.1 ± 3.33 | -17.7 ± 3.29 | -25.6 ± 3.32 | -20.5 ± 3.33 |
| Change at Week 36 | 0.0 ± 2.71 | -17.1 ± 3.09 | -17.1 ± 3.05 | -23.4 ± 3.10 | -17.3 ± 3.09 |
| Change at Week 48/ET | 1.7 ± 2.96 | -12.1 ± 3.37 | -12.1 ± 3.29 | -21.8 ± 3.35 | -20.0 ± 3.35 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting High-Density Lipoprotein Cholesterol (HDL-C) | 4.7 ± 3.34 | 37.9 ± 3.81 | 46.8 ± 3.82 | 50.5 ± 3.80 | 32.8 ± 3.82 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Change at Week 4 | 3.6 ± 3.38 | 39.3 ± 3.88 | 48.3 ± 3.86 | 55.4 ± 3.88 | 55.5 ± 3.90 |
| Change at Week 8 | 2.0 ± 3.18 | 32.1 ± 3.61 | 46.4 ± 3.63 | 54.3 ± 3.62 | 52.8 ± 3.64 |
| Change at Week 12 | 2.5 ± 3.19 | 31.4 ± 3.60 | 40.1 ± 3.66 | 49.0 ± 3.61 | 45.1 ± 3.65 |
| Change at Week 16 | 3.2 ± 3.46 | 45.8 ± 3.90 | 56.4 ± 3.93 | 64.2 ± 3.91 | 41.6 ± 3.91 |
| Change at Week 20 | 2.8 ± 3.27 | 45.0 ± 3.75 | 50.6 ± 3.76 | 58.2 ± 3.74 | 40.3 ± 3.73 |
| Change at Week 24 | 4.7 ± 3.34 | 37.9 ± 3.81 | 46.8 ± 3.82 | 50.5 ± 3.80 | 32.8 ± 3.82 |
| Change at Week 28 | 2.1 ± 3.47 | 35.8 ± 3.98 | 45.3 ± 3.96 | 49.5 ± 3.96 | 54.0 ± 3.99 |
| Change at Week 36 | 1.6 ± 3.25 | 30.8 ± 3.72 | 37.0 ± 3.71 | 43.1 ± 3.72 | 49.7 ± 3.73 |
| Change at Week 48/ET | 4.5 ± 3.53 | 25.4 ± 4.02 | 30.5 ± 3.98 | 34.3 ± 4.00 | 44.5 ± 4.01 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting Total Apolipoprotein B (ApoB) | 0.8 ± 2.57 | -9.5 ± 2.94 | -12.2 ± 2.89 | -18.3 ± 2.91 | -5.7 ± 2.91 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Change at Week 4 | -1.3 ± 1.99 | -10.3 ± 2.30 | -15.5 ± 2.24 | -18.5 ± 2.28 | -13.5 ± 2.29 |
| Change at Week 8 | -0.5 ± 2.26 | -11.0 ± 2.56 | -15.5 ± 2.54 | -20.3 ± 2.55 | -10.9 ± 2.56 |
| Change at Week 12 | 0.9 ± 2.53 | -8.5 ± 2.87 | -14.3 ± 2.86 | -14.8 ± 2.85 | -10.8 ± 2.87 |
| Change at Week 16 | 0.2 ± 2.30 | -12.8 ± 2.60 | -17.2 ± 2.57 | -20.6 ± 2.58 | -9.4 ± 2.58 |
| Change at Week 20 | 0.5 ± 2.61 | -13.0 ± 3.00 | -14.3 ± 2.96 | -19.3 ± 2.97 | -7.3 ± 2.95 |
| Change at Week 24 | 0.8 ± 2.57 | -9.5 ± 2.94 | -12.2 ± 2.89 | -18.3 ± 2.91 | -5.7 ± 2.91 |
| Change at Week 28 | 5.1 ± 2.98 | -9.0 ± 3.41 | -10.0 ± 3.35 | -16.3 ± 3.38 | -12.1 ± 3.38 |
| Change at Week 36 | 3.7 ± 2.68 | -7.8 ± 3.07 | -9.3 ± 3.00 | -15.4 ± 3.05 | -9.9 ± 3.04 |
| Change at Week 48/ET | 3.3 ± 2.75 | -4.7 ± 3.14 | -6.4 ± 3.06 | -12.2 ± 3.11 | -11.9 ± 3.11 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Percent Change From Baseline at Week 24 in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) | -0.1 ± 3.62 | 1.4 ± 4.14 | 3.9 ± 4.10 | -4.3 ± 4.13 | 7.3 ± 4.14 |
LS mean and SE were calculated using MMRM which included treatment arm, study visit, and baseline value as model terms and treatment by visit and treatment by baseline as interaction terms.
| percentage change | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Change at Week 4 | 0.6 ± 3.18 | 5.0 ± 3.67 | 1.1 ± 3.59 | 0.4 ± 3.66 | 3.2 ± 3.67 |
| Change at Week 8 | 1.7 ± 3.24 | 0.7 ± 3.68 | 0.6 ± 3.65 | -3.6 ± 3.69 | 7.4 ± 3.70 |
| Change at Week 12 | 1.8 ± 3.68 | 2.5 ± 4.16 | 2.5 ± 4.18 | 1.6 ± 4.16 | 3.2 ± 4.20 |
| Change at Week 16 | 1.5 ± 3.65 | 2.2 ± 4.11 | 0.4 ± 4.10 | -2.7 ± 4.11 | 3.2 ± 4.09 |
| Change at Week 20 | -0.3 ± 3.78 | 1.3 ± 4.35 | 4.0 ± 4.31 | -3.9 ± 4.33 | 7.2 ± 4.30 |
| Change at Week 24 | -0.1 ± 3.62 | 1.4 ± 4.14 | 3.9 ± 4.10 | -4.3 ± 4.13 | 7.3 ± 4.14 |
| Change at Week 28 | 1.6 ± 3.86 | 0.2 ± 4.42 | 6.1 ± 4.37 | -3.6 ± 4.41 | 2.0 ± 4.42 |
| Change at Week 36 | 1.6 ± 3.80 | 0.0 ± 4.33 | 5.3 ± 4.28 | -3.5 ± 4.35 | 5.7 ± 4.34 |
| Change at Week 48/ET | 1.7 ± 3.88 | 2.0 ± 4.43 | 6.9 ± 4.32 | -4.0 ± 4.40 | -0.1 ± 4.40 |
An adverse event (AE) was any untoward medical occurrence, which did not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) was an AE that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or was a medically important event or reaction. TEAEs were AEs that occurred following study drug administration or a pre-existing condition exacerbated following study drug administration.
| Participants | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| All TEAEs | 55 | 46 | 45 | 47 | 49 |
| Treatment-related TEAEs | 8 | 7 | 9 | 12 | 8 |
| Serious TEAEs | 5 | 2 | 5 | 7 | 5 |
| TEAEs leading to study drug discontinuation | 2 | 0 | 0 | 1 | 0 |
| Deaths | 0 | 0 | 1 | 2 | 1 |
Collected over Up to Week 48. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/87 (0%) | 5/87 (5.7%) | 55/87 (63.2%) |
| ARO-APOC3 10 mg Q12W | 0/67 (0%) | 2/67 (3%) | 47/67 (70.1%) |
| ARO-APOC3 25 mg Q12W | 1/67 (1.5%) | 5/67 (7.5%) | 44/67 (65.7%) |
| ARO-APOC3 50 mg Q12W | 2/66 (3%) | 7/66 (10.6%) | 48/66 (72.7%) |
| ARO-APOC3 50 mg Q24W | 1/66 (1.5%) | 5/66 (7.6%) | 48/66 (72.7%) |
| Event | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Aortic aneurysm ruptureVascular disorders | 0/87 | 0/67 | 0/67 | 0/66 | 1/66 |
| Artery dissectionVascular disorders | 0/87 | 0/67 | 0/67 | 0/66 | 1/66 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/87 | 0/67 | 0/67 | 1/66 | 0/66 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/87 | 0/67 | 0/67 | 1/66 | 0/66 |
| Completed suicidePsychiatric disorders | 0/87 | 0/67 | 0/67 | 1/66 | 0/66 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/87 | 0/67 | 0/67 | 1/66 | 0/66 |
| Acute coronary syndromeCardiac disorders | 0/87 | 0/67 | 0/67 | 0/66 | 1/66 |
| Myocardial infarctionCardiac disorders | 0/87 | 0/67 | 0/67 | 1/66 | 0/66 |
| Myocardial ischaemiaCardiac disorders | 0/87 | 0/67 | 0/67 | 1/66 | 0/66 |
| Coeliac artery aneurysmGastrointestinal disorders | 0/87 | 0/67 | 0/67 | 0/66 | 1/66 |
| Event | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W |
|---|---|---|---|---|---|
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 4/87 | 5/67 | 4/67 | 8/66 | 11/66 |
| COVID-19Infections and infestations | 12/87 | 8/67 | 11/67 | 9/66 | 6/66 |
| Upper respiratory tract infectionInfections and infestations | 7/87 | 3/67 | 7/67 | 2/66 | 9/66 |
| Urinary tract infectionInfections and infestations | 7/87 | 4/67 | 6/67 | 6/66 | 2/66 |
| HeadacheNervous system disorders | 3/87 | 2/67 | 3/67 | 4/66 | 5/66 |
| BronchitisInfections and infestations | 1/87 | 4/67 | 2/67 | 3/66 | 5/66 |
| Abdominal painGastrointestinal disorders | 0/87 | 0/67 | 0/67 | 4/66 | 1/66 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/87 | 0/67 | 1/67 | 2/66 | 4/66 |
| Back painMusculoskeletal and connective tissue disorders | 2/87 | 2/67 | 2/67 | 4/66 | 0/66 |
| CystitisInfections and infestations | 2/87 | 4/67 | 2/67 | 1/66 | 4/66 |
Full Analysis Set: All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W | Total |
|---|---|---|---|---|---|---|
| Mean | 58.9 ± 9.70 | 60.2 ± 11.71 | 61.3 ± 11.28 | 62.6 ± 10.53 | 61.3 ± 11.84 | 60.7 ± 10.99 |
| Sex: Female, Male(Participants) | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W | Total |
|---|---|---|---|---|---|---|
| Female | 41 | 31 | 30 | 29 | 23 | 154 |
| Male | 46 | 36 | 37 | 37 | 43 | 199 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 18 | 12 | 12 | 15 | 73 |
| Not Hispanic or Latino | 71 | 49 | 55 | 53 | 51 | 279 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W | Total |
|---|---|---|---|---|---|---|
| Race — White | 79 | 62 | 60 | 63 | 62 | 326 |
| Race — Black or African American | 4 | 2 | 2 | 0 | 0 | 8 |
| Race — American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Race — Asian | 3 | 2 | 3 | 1 | 1 | 10 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 | 2 |
| Race — Unknown | 0 | 0 | 0 | 0 | 1 | 1 |
| Race — Other | 1 | 1 | 0 | 2 | 1 | 5 |
| Mean Triglycerides (TG)(mg/deciliter (dL)) | Placebo | ARO-APOC3 10 mg Q12W | ARO-APOC3 25 mg Q12W | ARO-APOC3 50 mg Q12W | ARO-APOC3 50 mg Q24W | Total |
|---|---|---|---|---|---|---|
| Mean | 237.22 ± 76.179 | 253.15 ± 81.425 | 234.08 ± 72.746 | 250.25 ± 81.329 | 248.01 ± 80.553 | 244.10 ± 78.289 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Feb 2023, 16 months.
Results were first posted in Feb 2026, 3 years after primary completion. A results delay was requested in Feb 2024.
Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 16 months is above that.
Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plozasiran